Shenzhen Chipscreen Biosciences Co. Ltd. Class ASSE: 688321

Announcement on Voluntary Disclosure of Acceptance of the Clinical Trial Application for Chiglitazar Sodium Sustained-release Tablets

· Issued by Shenzhen Chipscreen Biosciences Co. Ltd. Class A via Shanghai Stock Exchange
Announcement on Voluntary Disclosure of Acceptance of the Clinical Trial Application for Chiglitazar Sodium Sustained-release Tablets

The abstract is for reference only. Please refer to the full text of the announcement on the very day.

Link of Full Text for Reference: View Attachment